首頁 > 市場調查報告書 > 製藥

靜脈注射鐵劑市場規模、佔有率和成長分析（按產品類型、適應症、分銷管道和地區分類）—產業預測（2026-2033 年）

市場調查報告書

商品編碼

1898062

靜脈注射鐵劑市場規模、佔有率和成長分析（按產品類型、適應症、分銷管道和地區分類）—產業預測（2026-2033 年）

Intravenous Iron Drugs Market Size, Share, and Growth Analysis, By Product Type (Iron Dextran, Iron Sucrose), By Indication (Chronic Kidney Disease, Inflammatory Bowel Disease), By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月22日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，靜脈注射鐵劑市場規模將達到 34.7 億美元，到 2025 年將達到 37.6 億美元，到 2033 年將達到 71.7 億美元，在預測期（2026-2033 年）內，複合年成長率為 8.4%。

靜脈注射鐵劑市場正經歷顯著成長，主要促進因素是缺鐵性貧血盛行率的上升。這種疾病會損害氧氣輸送，導致疲勞和認知障礙，從而刺激了人們對靜脈注射鐵劑等有效治療方法的興趣和需求。人口老化進一步加劇了這個問題，因為老年人由於飲食限制和健康併發症而面臨更高的風險。與口服補充劑不同，靜脈注射能夠更快、更有效地緩解症狀。此外，市場參與企業正致力於研發安全性更高、使用更便利的創新配方。策略合作和收購也在增加，使企業能夠擴展產品線和市場影響，從而服務更廣泛的客戶群。

靜脈注射鐵劑市場促進因素

推動靜脈鐵劑市場發展的關鍵因素是全球缺鐵性貧血發生率的不斷上升。這種疾病在某些人群中尤其普遍，例如孕婦、育齡婦女和慢性病患者。人們對缺鐵危害的認知不斷提高，以及靜脈注射鐵劑療法療效的證實，導致對這類治療方案的需求激增，從而促進了市場擴張。人們對靜脈鐵劑療法益處的日益了解，在塑造其在醫療保健領域的成長軌跡方面發揮關鍵作用。

制約靜脈鐵劑市場的因素

靜脈鐵劑市場面臨的主要限制因素是給藥相關的副作用風險。儘管這些藥物總體上具有公認的安全性，但仍可能發生超敏反應和輸注相關副作用，例如過敏反應、低血壓甚至過敏性休克。這些潛在併發症會阻礙醫護人員和患者選擇靜脈注射鐵劑治療，這在一定程度上限制了市場成長。為了解決這個問題，生產者和醫療機構必須實施嚴格的病患篩選、監測和給藥指南，以降低這些風險並提高病患安全。

靜脈注射鐵劑市場趨勢

靜脈注射鐵劑市場的一個顯著趨勢是，人們越來越關注以安全性和患者便利性為優先的創新鐵劑配方。製藥公司正加大研發投入，致力於開發能夠克服傳統靜脈注射鐵劑配方限制的先進治療方法。這些創新療法著重於透過延長給藥間隔、提高耐受性和最大限度降低過敏反應風險等方式來提高患者的依從性。因此，整個產業正致力於改善治療效果和患者的整體體驗，這反映了靜脈鐵劑治療領域向以患者為中心的理念轉變。

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2021-2023年營收年比比較
主要企業簡介
- 賽諾菲（法國）
- Pharmacosmos A/S（丹麥）
- 艾伯維公司（美國）
- 第一三共株式會社（日本）
- 輝瑞公司（美國）
- Zydus Lifesciences Limited（印度）
- 費森尤斯股份公司（德國）
- 梯瓦製藥工業股份有限公司（以色列）
- Akebia Therapeutics, Inc.（美國）
- 羅克韋爾醫療公司（美國）
- 美國攝政公司（美國）
- AdvaCare Pharma（美國）
- 拜耳股份公司（德國）
- F. Hoffmann-La Roche Ltd.（瑞士）
- 諾華公司（瑞士）
- Shield Therapeutics plc（英國）
- Galenica有限公司（瑞士）
- CSL有限公司（澳洲）
- AMAG製藥公司（美國）
- Covis Pharma GmbH（瑞士）

結論與建議

簡介目錄

Product Code: SQMIG35A2273

Intravenous Iron Drugs Market size was valued at USD 3.47 Billion in 2024 and is poised to grow from USD 3.76 Billion in 2025 to USD 7.17 Billion by 2033, growing at a CAGR of 8.4% during the forecast period (2026-2033).

The intravenous iron drugs market is witnessing significant growth, driven primarily by the rising prevalence of iron deficiency anemia, which significantly impacts global health. This condition impairs oxygen transport, causing fatigue and cognitive issues, thus increasing awareness and demand for effective treatment options like intravenous iron therapies. The aging population further exacerbates this issue, as older adults face greater risk due to dietary limitations and health complications. Unlike oral supplements, intravenous options provide quicker and more effective relief. Additionally, market players are focusing on research and development to introduce innovative formulations with better safety and convenience profiles. Strategic collaborations and acquisitions are also on the rise, enabling companies to enhance their product offerings and expand their market presence, catering to a broader customer base.

Top-down and bottom-up approaches were used to estimate and validate the size of the Intravenous Iron Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Intravenous Iron Drugs Market Segments Analysis

Global Intravenous Iron Drugs Market is segmented by product type, indication, distribution channel and region. Based on product type, the market is segmented into Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, and Other Product Types. Based on indication, the market is segmented into Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Diseases. Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Intravenous Iron Drugs Market

A significant factor propelling the intravenous iron drugs market is the growing incidence of iron deficiency anemia globally. This condition is particularly prevalent among specific demographics, including pregnant women, women of childbearing age, and individuals suffering from chronic illnesses. As awareness regarding the implications of iron deficiency continues to rise, alongside the proven efficacy of intravenous iron treatments, demand for these therapeutic options has surged, thereby contributing to the expansion of the market. This increasing recognition of the benefits of intravenous iron therapy plays a vital role in shaping its growth trajectory within the healthcare sector.

Restraints in the Intravenous Iron Drugs Market

A significant constraint in the intravenous iron drugs market is the risk of adverse reactions related to their administration. Despite the overall safety profile of these medications, possible hypersensitivity reactions and infusion-related side effects could arise, including allergic responses, hypotension, and even anaphylaxis. Such potential complications may discourage healthcare professionals and patients from opting for intravenous iron therapy, thereby creating a degree of limitation in market growth. To address this concern, it is crucial for manufacturers and healthcare providers to implement stringent patient selection, monitoring, and administration guidelines that aim to reduce these risks and enhance patient safety.

Market Trends of the Intravenous Iron Drugs Market

A prominent trend in the intravenous iron drugs market is the heightened emphasis on innovative iron formulations that prioritize safety and patient convenience. Pharmaceutical companies are increasingly channeling resources into research and development to create advanced therapies that overcome the limitations associated with traditional intravenous iron products. These innovations focus on enhancing patient compliance through features such as extended dosing intervals, better tolerability, and minimized risk of hypersensitivity reactions. As a result, the industry is dedicated to improving treatment outcomes and overall patient experience, reflecting a shift towards more patient-centric approaches in intravenous iron therapy.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Intravenous Iron Drugs Market Size by Product Type & CAGR (2026-2033)

Market Overview
Iron Dextran
Iron Sucrose
Ferric Carboxymaltose
Other Product Types

Global Intravenous Iron Drugs Market Size by Indication & CAGR (2026-2033)

Market Overview
Chronic Kidney Disease
Inflammatory Bowel Disease
Cancer
Other Diseases

Global Intravenous Iron Drugs Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Global Intravenous Iron Drugs Market Size & CAGR (2026-2033)

North America (Product Type, Indication, Distribution Channel)
- US
- Canada
Europe (Product Type, Indication, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product Type, Indication, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product Type, Indication, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Product Type, Indication, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pharmacosmos A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Lifesciences Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius SE & Co. KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Akebia Therapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Rockwell Medical, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
American Regent, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AdvaCare Pharma (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shield Therapeutics plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Galenica Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AMAG Pharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Covis Pharma GmbH (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments